Alpha-1 Antitrypsin Deficiency: State of the Art

Activity Details
  • Credit Amounts:
    • CME: 1.00
    • Other: 1.00
  • Cost: Free
  • Release: Jun 16, 2021
  • Expires: Oct 31, 2021
  • Estimated Time to Complete:
    1 Hour(s)
  • Average User Rating:
    (2 Ratings)

Faculty

James K.  Stoller James K. Stoller, M.D., M.S.
Chairman, Education Institute, Cleveland Clinic
Jean Wall Bennett Professor of Medicine
Samson Global Leadership Academy Endowed Chair
Cleveland Clinic Lerner College of Medicine

Needs Statement

Alpha-1 Antitrypsin Deficiency (AATD) is a genetic disorder in which the vast majority of patients are unidentified or misdiagnosed, and experience significant delays in diagnosis. This is a pertinent and timely clinical issue, as specific therapeutic intervention is available for AATD patients. Also, the treatment landscape is continuing to evolve, with active clinical research and emerging therapies for associated lung and liver disease.

Target Audience

Primary care, family medicine, and pulmonology physicians, nurse practitioners, and other allied health care professionals providing care for AATD patients. 

 

Objectives

Upon completion of this educational activity, participants will be able to:

  • Describe the pathogenesis and pathophysiology of alpha-1 antitrypsin deficiency (AATD).
  • Identify appropriate patients who would be candidates for testing for AATD. 
  • Recognize common disease manifestations of AATD.
  • Review current guidelines for diagnostic testing and management of individuals with AATD.

Accreditation

In support of improving patient care, this activity has been planned and implemented by UK HealthCare CECentral and Mercury Market Development LLC. University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ACGME Competencies

  • Patient care
  • Medical knowledge

Other
UK Healthcare CECentral certifies this activity for 1.00 hour of participation.

Faculty Disclosure

James Stoller, M.D., M.S. (speaker) has relevant financial relationships with commercial interests as follows:


Takeda, Grifols, CSL Behring, Insmed, Vertex, 23andMe, InhibRx, Arrowhead, Dicerna - Consultant - Consultant Fee

CSL Behring – Investigator/Research - Grant Funding

Grifols - Speaker - Honorarium

No other speakers, authors, planners or content reviewers have any relevant financial relationships to disclose. (Revise this paragraph, as appropriate, for the activity.)

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias.(Use this first sentence if applicable) Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made toprovide participants with information that might be of potential importance to their evaluation of a presentation. 

Acknowledgement

This activity is jointly provided by the University of Kentucky and Mercury Market Development LLC.

Supported by an unrestricted educational grant from Takeda Pharmaceuticals North America, Inc.